Bio Rad Accumulated Other Comprehensive Income Over Time
| BIO Stock | USD 332.91 7.33 2.25% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Bio Rad Performance and Bio Rad Correlation. Bio |
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.412 | Earnings Share (28.06) | Revenue Per Share 90.815 | Quarterly Revenue Growth 0.028 | Return On Assets 0.0186 |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Accumulated Other Comprehensive Income Analysis
Compare Bio Rad Laboratories and related stocks such as Tandem Diabetes Care, DexCom Inc, and Inspire Medical Systems Accumulated Other Comprehensive Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TNDM | (3.1 M) | (3.1 M) | (5 M) | (7.6 M) | 8 K | 20 K | (1000) | (25.5 M) | (13 K) | 122 K | 220 K | (616 K) | (1.8 M) | 1.4 M | 1.4 M |
| DXCM | (932 K) | (80 K) | (100 K) | (100 K) | (100 K) | (300 K) | (1000 K) | (2.6 M) | 1.5 M | 2.3 M | 3.2 M | 500 K | (11.6 M) | (16.7 M) | (15.9 M) |
| INSP | (681 K) | (681 K) | (681 K) | (681 K) | (681 K) | (681 K) | (681 K) | (810 K) | (52 K) | 102 K | 29 K | (55 K) | (86 K) | 800 K | 840 K |
| PEN | 796 K | 796 K | 796 K | 796 K | (864 K) | (2.1 M) | (4.7 M) | 1.6 M | (1.9 M) | (2.3 M) | 2.5 M | (2.6 M) | (8.1 M) | (3.2 M) | (3 M) |
| CNMD | (1.7 M) | (26.3 M) | (27.6 M) | (17.6 M) | (39.8 M) | (53.9 M) | (58.5 M) | (49.1 M) | (55.7 M) | (59.3 M) | (63.7 M) | (54.2 M) | (57.9 M) | (50.2 M) | (47.7 M) |
| BRKR | (2.9 M) | 142.5 M | 137.8 M | 182.4 M | 28.2 M | (44.2 M) | (75.9 M) | 27 M | 17 M | (25.5 M) | 3.7 M | (8.2 M) | 14.8 M | 6 M | 5.7 M |
| ZBH | 782 M | 271.4 M | 343.9 M | 367.1 M | 85.9 M | (329 M) | (434 M) | (83.2 M) | (187.4 M) | (241.9 M) | (297.8 M) | (231.6 M) | (179.3 M) | (191 M) | (181.4 M) |
| GKOS | 2 K | 2 K | 2 K | 2 K | 44 K | 51 K | 648 K | (591 K) | 738 K | 1.3 M | 1 M | 15 K | (3 M) | 1.2 M | 1.2 M |
| NARI | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (54.2 M) | 4 K | (402 K) | 849 K | 8.9 M | 9.3 M |
| PODD | (88 K) | (22.9 M) | (27.9 M) | (34.5 M) | (22.9 M) | (654 K) | (726 K) | (493 K) | (2.9 M) | (1.2 M) | 5.5 M | (2.2 M) | 20 M | 8 M | 8.4 M |
| GMED | (718 K) | (1.2 M) | (767 K) | (1 M) | (1.7 M) | (2 M) | (8.6 M) | (6.9 M) | (7.2 M) | (2.9 M) | 4 M | (6.8 M) | (24.6 M) | (10.2 M) | (9.7 M) |
| NVCR | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (4.3 M) | (1.5 M) | (1.9 M) | (1.3 M) | (1.4 M) | (2.8 M) | (3.8 M) | (3.2 M) | (2.4 M) | (5.5 M) | (5.2 M) |
| STE | (6.5 M) | 13.6 M | (4.1 M) | 4.5 M | (66.7 M) | (68.2 M) | (240.7 M) | 11.7 M | (159.8 M) | (235.5 M) | (61.2 M) | (209.8 M) | (320.7 M) | (328.7 M) | (312.2 M) |
| ANIK | (2.4 M) | (3.1 M) | (2.7 M) | (1.7 M) | (4.5 M) | (6.6 M) | (7.3 M) | (4.8 M) | (5.5 M) | (5.9 M) | (4.5 M) | (5.7 M) | (6.4 M) | (5.9 M) | (6.2 M) |
| ITGR | (13.9 M) | 8.9 M | 12.9 M | 14.4 M | 9.1 M | 1.4 M | (16 M) | 52.2 M | 33 M | 20 M | 52.7 M | 27.2 M | 5.3 M | 20.2 M | 21.2 M |
Bio Rad Laboratories and related stocks such as Tandem Diabetes Care, DexCom Inc, and Inspire Medical Systems Accumulated Other Comprehensive Income description
Gains and losses not included in net income that are recorded in shareholders' equity, reflecting changes in the value of assets or liabilities that are not realized.My Equities
My Current Equities and Potential Positions
| Bio Rad Laboratories | BIO |
| Classification | Measuring and Control Equipment |
| Location | California; U.S.A |
| Exchange | New York Stock Exchange |
USD 332.91
Check out Bio Rad Performance and Bio Rad Correlation. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Bio Rad technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.